Phase I study of lapatinib plus trametinib in patients with KRAS -mutant colorectal, non-small cell lung, and pancreatic cancer
ConclusionLapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed and pharmacodynamic target engagement was demonstrated.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Drugs & Pharmacology | HER2 | Lung Cancer | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | Study | Toxicology